Execute

and Deliver
Investor Presentation

May 9, 2018

1
 Cautionary Note Regarding Forward-Looking Statements

This presentation includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally
can be identified by the use of words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,” “estimate,” “continue,” “guidance,” “future,” other words of
similar meaning and the use of future dates. Forward-looking statements in this presentation include, but are not limited to, statements about the company’s
anticipated financial results for 2018, including net sales from continuing operations, adjusted EBITDA from continuing operations and adjusted earnings per
share from continuing operations, anticipated strong shoulder sales growth in 2018, and anticipated U.S. lower extremities improvement in 2018 and the
company’s need for additional capital. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking
statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by
such statement. Applicable risks and uncertainties include, among others, the failure of the company’s 2017 U.S. sales force additions to achieve expected
results, focus on core product portfolio and incentives to drive U.S. lower extremities and biologics sales or delay in realization thereof; the risk of continued
supply constraints; the failure to integrate the legacy Wright and Tornier businesses and realize net sales synergies and cost savings from the merger with Tornier
or delay in realization thereof; operating costs and business disruption as a result of the merger, including adverse effects on employee retention and sales force
productivity and on business relationships with third parties; integration costs; actual or contingent liabilities; adverse effects of diverting resources and attention
to providing transition services to the purchaser of the large joints business; the adequacy of the company’s capital resources and need for additional financing;
the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; failure to achieve the
anticipated commercial sales of our AUGMENT® Bone Graft products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product
liability claims and product recalls; pending and threatened litigation; risks associated with the metal-on-metal master settlement agreement and the settlement
agreement with the three settling insurers; risks associated with the subsequent metal-on-metal settlement agreements and ability to obtain the additional new
insurance proceeds contingent thereon; risks associated with international operations and expansion; fluctuations in foreign currency exchange rates; other
business effects, including the effects of industry, economic or political conditions outside of the company’s control; reliance on independent distributors and sales
agencies; competitor activities; changes in tax and other legislation; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form
10-K for the year ended December 31, 2017 filed by Wright with the SEC on February 27, 2018 and subsequent SEC filings by Wright, including without limitation
its Quarterly Report on Form 10-Q for the quarter ended April 1, 2018. Investors should not place considerable reliance on the forward-looking statements
contained in this presentation. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks
and uncertainties. The forward-looking statements in this presentation speak only as of the date of this presentation, and Wright undertakes no obligation to
update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration to these risks and uncertainties.

2
 Note on Non-GAAP Financial Measures
Wright uses non-GAAP financial measures, including constant currency net sales, gross margin from continuing operations, as adjusted,
and EBITDA from continuing operations, as adjusted. Wright’s management team believes that the presentation of these measures
provides useful information to investors and that these measures may assist investors in evaluating the company’s operations, period over
period. EBITDA is calculated by adding back to net income charges for interest, income taxes and depreciation and amortization
expenses. While it is not possible to reconcile the adjusted EBITDA forecast in this presentation to the nearest metric under U.S.
generally accepted accounting principles (GAAP) without unreasonable effort, the adjusted EBITDA forecast excludes non-cash share
based compensation expense and non-operating income and expense, all of which may be highly variable, difficult to predict and of a size
that could have substantial impact on the company’s reported results of operations for a period. Investors should consider these non-
GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in
accordance with GAAP. Reconciliations of the non-GAAP financial measures used in this presentation to most comparable GAAP
measures can be found on our website.

3
Wright is Leader in 3 of the
~$8B
Global extremities/
Orthopaedic Markets biologics market

LOWER EXTREMITIES UPPER EXTREMITIES BIOLOGICS

#1 #2 Leader
Wright position in Wright position in Highly differentiated
foot & ankle market shoulder market biologics portfolio

4
 Recognized leader in high-growth
extremities & biologics market
Differentiators
That Matter Global footprint with the largest
specialized direct sales force in the U.S.

Leading technologies in upper

and lower extremities portfolio

Strong R&D pipeline

Strong emphasis on medical education

THE

ONLY
PLAYER WITH A SINGULAR FOCUS
ON
EXTREMITIES-BIOLOGICS
5
In High-Growth Markets, We’re Positioned to Grow
Faster than Market
Available Market ~$8B (est.)
Multiple continued growth opportunities

7 – 9% MKT CAGR 8 – 10% MKT CAGR 5 – 6% MKT CAGR

Upper Extremities
2018 Initiatives
Extend shoulder leadership
position
• PERFORM™ Reversed
Rollout
• Drive BLUEPRINT™
Adoption
Lower Extremities
2018 Initiatives
Restore core U.S. foot &
ankle business
• New rep additions
• New product contributions
• Continue to grow Total
Ankle Replacement
Biologics
2018 Initiatives
Increase AUGMENT®
penetration
• Leverage opportunities for
selling biologics across
upper and lower
extremities portfolio

$2.7B $3.7B $1.7B $2.8B $1.1B $1.4B

2014 2019 est. 2014 2019 est. 2014 2019 est. 6
2018 Strategic Priorities for Growth

Key Priorities
Revenue Cash
1. Continued strong Vision 1. Improve inventory and
shoulder growth, instruments efficiency
Your First Choice
driven by PERFORM™ in Extremities 2. Improve DSO
Reversed glenoid & Biologics
3. Leverage SG&A
2. “Restore the Core” in
U.S. Lower Extremities –
sales force performance
3. Improve International growth
4. Drive enabling technologies

Key Longer-Term Financial Objectives

Mid-teens global Adj. Gross Margins in Expand Adj. EBITDA margins to

revenue growth
Contents are Confidential – Wright Internal Use Only
high 70s% range ~20% late 2019 7
 STRONG
new product pipeline to drive
GROWTH
opportunities

Lower Extremities
PROstep™ MIS (Minimally Invasive Surgery) (Anticipated launch: 3Q 2018)
INFINITY™ BIOFOAM™ 3D (Anticipated launch: 4Q 2018)
INVISION™ Revision Ankle System (in rollout)
PROPHECY™ INVISION™ Revision Ankle (Anticipated launch: 2Q 2018)
ORTHOLOC™ 3Di Ankle Fracture LP System (in rollout)
SALVATION™ Limb Salvage Line Extensions (in rollout)

Upper Extremities
Biologics
PERFORM™ Reversed Glenoid (in rollout) AUGMENT® (in rollout)
SIMPLICITI™ Shoulder System (in rollout) AUGMENT® Injectable (pursuing
BLUEPRINT™ 3D Planning (staged rollout of PMA-Supplement with Panel Track)
new modules throughout 2018)

Contents are Confidential – Wright Internal Use Only 8

A Look Into Upper Extremities
LOWER EXTREMITIES

UPPER EXTREMITIES

BIOLOGICS

9 9
Product Pipeline:
Upper Extremities

New REVIVE™ Revision Shoulder System PERFORM™ Reversed Glenoid

Convertible, fully adjustable revision stem to Anatomically shaped, porous metal
address complex revisions fixation for difficult glenoid anatomy
Anticipated Pre-Market
Limited Launch: 4Q 2018 Continued rollout throughout 2018

BLUEPRINT™ 3D Planning Software PyroCarbon Humeral Head Clinical Study

Surgeon controlled, patient-specific Proprietary pyrocarbon material providing low
instrumentation for accurate positioning of friction, wear-resistant articulating surface to
glenoid implant extend implant life

Scaled adoption of existing

platform; launch new software
modules throughout 2018 US IDE clinical trial underway
10
SIMPLICITI™ Shoulder:
a highlight of our upper extremities product portfolio

True Bone Preservation

Canal-sparing design provides maximal bone
preservation and early intervention options

Simplified Anatomic Alignment

Fewer variables while increasing
accuracy and reproducibility

99% OF THE PEOPLE WHO HAVE A

Opens new SHOULDER REPLACEMENT FOR ARTHRITIS
market category GET PAIN RELIEF AND SAY THEY
Expands patient pool WISH THEY HAD DONE IT SOONER.
surgeons willing to treat Farmer KW, Hammond JW, Queale WS, Keyurapan E, McFarland EG. Shoulder arthroplasty versus
hip and knee arthroplasties: a comparison of outcomes. Clin Orthop Rel Res 2007;455:183-9.

MARKET OPPORTUNITY (U.S.):

$200M-$250M 11
PERFORM™ Reversed Glenoid:
designed to address all glenoid bone loss

Fixation
Long-term stability with ADAPTIS™
Integrated Porous Metal

Augmentation
Specifically shaped for treating
challenging glenoid anatomy

Orientation
Circular design and independent central screw
allows for an infinitely adjustable construct

LAUNCH UNDERWAY – ADDRESSES LARGEST

SEGMENT WITHIN SHOULDER REPLACEMENT
12
The BLUEPRINT™ Difference: Speed & Scalability

BLUEPRINT™ ADVANTAGES COMPETITIVE OFFERINGS

Automated, surgeon-controlled software 3D reconstruction Engineer-driven 3D reconstruction
Real-time planning access Delayed planning access
Side-by-side plan comparisons Single plan review only
Bone density visualization No bone density visualization
Humeral & Glenoid automated motion simulation Manual, limited motion simulation
13
BLUEPRINT™ is the Foundation for Comprehensive Digital Ecosystem

BENEFITS MAY INCLUDE:

Hospital/Surgeon Patients Wright Medical
Reduced costs Improved outcomes, Reduced Inventory
reduced surgical time Improved growth / profitability
Improved outcomes
Enhanced physician- Enhanced customer retention
Enhanced clinical
patient connectivity
evidence
Increased patient
education

POST-OPERATIVE
MEDICAL MONITORING

DIGITAL ECOSYSTEM EDUCATION

ANALYTICS
Rich pipeline under development
VIRTUAL
and patent pending to support SURGICAL
PLANNING
patient outcomes

14
A Look Into Lower Extremities
LOWER EXTREMITIES

UPPER EXTREMITIES

BIOLOGICS

15 15
Product Pipeline: Lower Extremities and Biologics
PROstep™ MIS
Anticipated Launch: 3Q 2018

INFINITY™ BIOFOAM™ 3D
Anticipated Launch: 4Q 2018

INVISION™ Revision Ankle System

Ongoing rollout throughout 2018

PROPHECY™ INVISION™ Revision Ankle

Anticipated Launch: 2Q 2018

ORTHOLOC™ 3Di Ankle Fracture System

Ongoing rollout throughout 2018

SALVATION™ Limb Salvage Line Extensions

Ongoing rollout throughout 2018

AUGMENT® Injectable
Anticipated Launch: TBD – PMA-Supplement with Panel
Track
* Panel Track Supplement does not necessarily result in a panel meeting. It affords
FDA additional time to review the submission beyond 180 days. The current
average for Panel Track Supplement review and approval is 300+ days.

16
 INBONE™, INFINITY™ & INVISION™:
completing the options

Total Ankle Replacement

Designed to relieve pain and preserve Continuum of Care
motion in arthritic ankle joint

High growth, underserved

Powered by accuracy of PROPHECY™

patient specific guides

INVISION™ revision ankle

CURRENT MARKET (U.S.): ~$90M

MARKET OPPORTUNITY (U.S.): ~$500M
17
 SALVATION™ Limb Salvage:
promising new lower extremities product portfolio

Plating System

Fusion Bolts
First comprehensive solution for Charcot & Beams
arthropathy and advanced midfoot reconstruction

Large, underserved market

High ASP and resistant to price pressure

Full rollout in progress

External Fixator

THERE ARE AN ESTIMATED 51,000

NEW CHARCOT PATIENTS PER YEAR IN U.S.
IT’S A GLOBAL EPIDEMIC WITH RAPID GROWTH.
CURRENT MARKET (U.S.): http://www.diabetes.org

$60M-$80M 18
 INBONE™, INFINITY™ & INVISION™
Total Ankle Replacement
Continuum of Care

Technologically
Advanced SALVATION™ Limb Salvage
Promising new lower extremities product portfolio
Products
Expected to
Plating Fusion Bolts
Outperform External Fixator System & Beams

Market
AUGMENT®
Alternative to autograft in
ankle and hindfoot fusion
19
 Restore growth in core U.S. foot and ankle business
U.S. sales force execution and new product launches

Focus on Execution
Improve sales force
productivity
~50% of US lower
extremities direct sales
force now focused on Ongoing &
selling core products New Product
Launches
Compensation plan is
incentivized for growth MIS
Ankle Fracture
INVISION™
SALVATION™
AUGMENT®
20
Opportunity for Significant
Leverage Going Forward
Key Drivers
Return on previous investments
> 50% OF OPERATING EXPENSE
CAN BE HIGHLY LEVERAGED
Sizing the Opportunity
% OF OP EXPENSE

AUGMENT®
Depreciation R&D
International Expansion Amortization Sales Force
14% 30%
Sales Force
Medical Education
Non-EBITDA 100% Re-invest at rate of sales
Hubs
Sales Management, Distribution
Leverage existing infrastructure Marketing, Med Education G&A
24% 32%

Leverage Significant Leverage

21
Cash and Liquidity Position

Major USES of cash expected in 2018: LIQUIDITY as of Q1 2018:

October 2016 Metal-on-Metal (MoM) $138M

$39M
Fund remaining MoM from cash Cash
October 2017* MoM Balance
Fund remaining MoM from cash
$28M *Comprised of $89.75M max settlement amount minus the $30M of anticipated insurance proceeds not
yet received as of 12/31/17; ~$28M due in 2018 (net of $17M proceeds received as of 4/30/18) and ~$140M*
$47M due in 2019.
Outstanding
$42M
BioMimetic Payment Revolver Capacity
Revenue milestone payment when TTM cumulative global sales reach *Added $40M additional capacity May 2018
$40 million

IMASCAP Milestone Payment $30.75M*

$12M
Potential milestone payment if certain development milestones are Insurance settlement
reached
*Received May 8, 2018

EXCLUDING ABOVE ITEMS AND OTHER DISC OPS, EXPECT TO BE CASH FLOW POSITIVE IN 2018
22
 Clear path to high-growth and
profitability
with more levers coming into play

STEP STEP STEP

1 2 3

Sustain revenue Maintain gross Leverage

growth/minimize margins in high existing
disruption 70s% range resources

Key Longer-Term Financial Objectives

MID-TEENS TOP-LINE
GROWTH adjusted

ADJ. GROSS MARGIN ~20% EBITDA margins

late 2019
HIGH 70s% RANGE

23
2018 annual guidance

Net Sales Adj. EBITDA

from Continuing from Continuing
Operations(1) Operations(1,2)

$800 million to $104 million to

$812 million $111 million

$
1 Guidance range communicated on 5/9/2018. The fact that we include these projections in this presentation should not be taken to mean that these amounts continue to be our projections as of any subsequent date.
2 Adj. EBITDA from continuing operations, which is measured by adding back to net income/loss from continuing operations charges for interest, income taxes, depreciation and amortization expenses, non-cash share-based
compensation expense, non-operating income and expense, and transaction and transition costs.
24
Advancing toward our goals

1Q 2018
Non-GAAP Results
from Continuing Ops. Longer-Term Goals

SALES GROWTH 9.2%* Mid-teens

ADJ. GROSS MARGIN 79.7% High 70s% range

Adj. EBITDA margins of

ADJ. EBITDA MARGIN 13.4%
approximately 20% late 2019

* Constant currency sales growth

25
Wright Medical:
Execute and Deliver

Leader in 3 of the fastest-growing

orthopaedic markets

Multiple growth drivers via new

product pipeline

On a faster path to profitability,

with a stronger financial profile

26
For additional information,
please contact:

Julie (Tracy) Dewey

Chief Communications Officer
julie.dewey@wright.com
(901) 290-5817

www.wright.com • NASDAQ: WMGI

27
Execute
and Deliver
Investor Presentation

May 9, 2018

28